Source - LSE Regulatory
RNS Number : 7835T
Redx Pharma plc
29 March 2021




("Redx" or "the Company")


Redx Pharma to present at the American Association for Cancer Research Annual Meeting


Alderley Park, 29 March 2021 Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, today announces that it will present a poster entitled 'Mechanism of action of RXC004, a Wnt pathway inhibitor, in genetically-defined models of cancer' at the  American Association for Cancer Research (AACR) Annual Meeting, being held virtually on 10 April 2021.


The poster relates to the Company's lead oncology candidate, RXC004, a selective, orally bioavailable porcupine inhibitor targeting the Wnt signalling pathway. The poster will present preclinical data on the potential for the direct tumour-targeting effects of RXC004 in genetically defined models of cancer.


Poster presentation:

Title: Mechanism of action of RXC004, a Wnt pathway inhibitor, in genetically-defined models of cancer

Abstract: #998

Session name and category: Session PO.ET02.02 - Cellular Responses to Anticancer Drugs


The abstract is available via the AACR annual meeting website, here:!/9325/presentation/2070


Copies of the poster will be available on the scientific publication page of Redx's website following the conference at


For further information, please contact:

Redx Pharma Plc 

T: +44 1625 469 918

Iain Ross, Chairman

Lisa Anson, Chief Executive

James Mead, Chief Financial Officer

SPARK Advisory Partners (Nominated Adviser)

 T: +44 203 368 3550

Matt Davis/Adam Dawes

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/Chris Lee/David Wilson

Panmure Gordon (UK) Limited (Joint Broker)

T: +44 20 7886 2500

Rupert Dearden/Freddy Crossley/Emma Earl

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Ciara Martin




About RXC004

RXC004 is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. Aberrant Wnt signalling contributes directly to tumour growth and plays an important role in immune resistance to treatment with immuno-oncology agents such as anti-PD-1 checkpoint inhibitors.


By selecting patients with tumours that have high Wnt ligand dependency, such as tumours with mutations in the RNF43 gene and fusions in the RSPO gene family, RXC004 has an opportunity to directly target tumour in addition to having an immune-enhancing effect.


RXC004 is currently in a phase 1 study, with top line data expected in H1 2021. Clinical proof-of-concept studies in genetically-selected patients with metastatic colorectal cancer (monotherapy and immuno-oncology combination), genetically selected pancreatic cancer and all comers biliary cancer are expected to initiate following completion of phase 1.


About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.


The Company's  core capability  of converting  medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.